Blowing the Whistle on Fen-Phen: An Exploration of MeritCare's Reporting of Linkages between Fen-Phen and Valvular Heart Disease

By Johnson, Carrie E.; Sellnow, Timothy L. et al. | The Journal of Business Communication, October 2004 | Go to article overview

Blowing the Whistle on Fen-Phen: An Exploration of MeritCare's Reporting of Linkages between Fen-Phen and Valvular Heart Disease


Johnson, Carrie E., Sellnow, Timothy L., Seeger, Matthew W., Barrett, M. Scott, Hasbargen, Kathryn C., The Journal of Business Communication


This study of the process resulting in the Food and Drug Administration's ban of the diet drug fen-phen following the whistle-blowing of MeritCare, a regional health system in Forgo, North Dakota, expands the concept of whistle-blowing to include external stakeholders who publicly expose problems or errors. The investigation evaluates the conditions surrounding the health system's decision to make public the technician's findings; its whistle-blowing procedures, retaliation fears, perceived need for enhanced credibility, and commitment to an ethic of significant choice are chronicled. The authors conclude that external stakeholders may enact many of the processes found in employee whistle-blowing and that consumer protection appears to be an important value in controversial whistle-blowing decisions. The authors also suggest that traditional notions of whistle-blowing are too narrow.

Keywords: whistle-blowing; ethics; health communication; crisis; credibility

**********

Organizations often face information that exposes problems or wrongdoing or represents dissent. Messages signaling problems or wrongdoing frequently come from internal sources such as employees or from related agencies and organizations aware of problems or wrongdoing. When the organization refuses to take appropriate action in response to these messages, insiders or outsiders may call broader attention to the issue by blowing the whistle. The communicative process of blowing the whistle is critical for organizations and societies seeking to monitor areas of emerging risk that are threatening to an organization's established routines and assumptions (Jensen, 1987; Miceli & Near, 1992; Redding, 1985; Seeger 1997).

The objective of the analysis presented in this article is to examine the public disclosure of serious side effects associated with the combined use of fenfluramine and phentermine, also known as fen-phen, a prescription weight loss drug cocktail produced and actively promoted by Robins Pharmaceuticals and Wyeth-Ayerst, both divisions of American Home Products. In the 1990s, fen-phen was widely prescribed, with as many as 18 million prescriptions written in 1996 alone (Pitts, Crosby, Laufenberg, Meidinger, & Monson, 1998). Although the two drugs had never been approved by the Food and Drug Administration (FDA) for combined use, individual physicians exercising their prerogative to prescribe both drugs in tandem, with the encouragement of American Home Products, made fen-phen one of the pharmaceutical industry's best-selling products (Pitts et al., 1998). These physicians saw fen-phen as an effective prescription for treating obesity. However, in the winter of 1997 an echocardiography technician working for MeritCare Health System (MeritCare) in Fargo, North Dakota, discovered what appeared to be a relationship of fen-phen usage to valvular heart disease. MeritCare staff, expressing serious concern on one hand and serious reservations about the implications of making such an accusation on the other hand, based their decisions on the opinions of several medical, legal, and communication staff members. This group of individuals is noted in this study as the Issues Management Team. Concerned about its ability to draw sufficient attention to the medical risks of taking fen-phen, MeritCare turned for assistance to the world famous Mayo Clinic (Mayo), in Rochester, Minnesota. This collaboration resulted in an article published in the New England Journal of Medicine and a public warning about the dangers of fen-phen usage. In September 1997, the FDA requested that American Home Products withdraw fen-phen from the market (see Table 1).

We focus our analysis on MeritCare's warning about the danger of fen-phen usage as a form of whistle-blowing. Although the whistle-blowers in this case were not employees of the company producing this dangerous product, we argue that this case represents a kind of external or outsider whistle-blowing that reaches beyond the traditional internal form. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Blowing the Whistle on Fen-Phen: An Exploration of MeritCare's Reporting of Linkages between Fen-Phen and Valvular Heart Disease
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.